-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Downgrades Fulcrum Therapeutics to Hold, Lowers Price Target to $3

Benzinga·06/02/2026 17:57:04
Listen to the news
Stifel analyst James Condulis downgrades Fulcrum Therapeutics (NASDAQ:FULC) from Buy to Hold and lowers the price target from $25 to $3.